2018 performance

Reports on healthcare service assessment – prepared in 2018

Qualification of healthcare services into the health benefit package:

• educational service in diabetes patients in outpatient specialist care;
• liquid cytology as part of a cervical cancer prevention health programme;
• SATRO ECG diagnostic method consisting of ECG analysis and early detection of heart diseases in primary healthcare;
• C-Ig-FISH genetic test (set of probes) (Cytoplasmic Immunoglobulin FISH) in the diagnosis of lymphatic cell tumours originating from plasma cells in outpatient specialist care;
• transcatheter electrosurgery of the bladder tumour in blue light using a photosensitiser (TURBT-PDD) in the hospital treatment;
• telemetry patient monitoring with an implanted automatic cardioversion or defibrillation system (ICD) or a cardiac resynchronisation system with defibrillation function (CRT-D) in outpatient specialist care;
• monitoring of L-asparaginase activity in patients with lymphoproliferative diseases – indications according to ICD-10 codes: C91.0, C83, C83.0- C83.2, C83.4 – C83.9, C85, C85.0, C85.1, C85.7, C85.9 in outpatient specialist care (AOS);
• 1) invasive preoperative diagnosis to locate the epileptogenic focus – placement of intracranial electrodes for long-term video-EEG monitoring; 2) surgical removal of the epileptogenic focus (one procedure) with intraoperative EEG monitoring, the so-called electrocorticography with simultaneous functional brain monitoring (MEP, SSEP, BAEP, evoked  speech function) – in epilepsy (ICD-10: G40.0, G40.1, G40.2), in hospital treatment;
• bronchial thermoplasty in severe asthma in hospital treatment;
• treatment of diabetic foot syndrome in outpatient specialist care and hospital treatment;

Removal of healthcare services from the health benefit package:

• active substance: “Erwinia L-asparaginase – removal of procedures from hospital treatment;
• active substance: mitoxantronum – removal of procedures from hospital treatment.

Change of health technologies:

• computed tomography (CT) and magnetic resonance imaging (MRI) in outpatient specialist care;
• in oncological indications: C50, C79.8, D05, D48.6 – breast cancer in primary healthcare, outpatient specialist care, hospital treatment;
• in oncological indications: C34 lung cancers in primary healthcare, outpatient specialist care, hospital treatment;
• in the scope of palliative and hospice care;
• in the scope of therapeutic rehabilitation – primary physiotherapeutic care.

Changes in organisation of service provision:

• development (in consultation with stakeholders) of comprehensive oncological care in the field of breast neoplasms;
• development (in consultation with stakeholders) of comprehensive oncological care in the field of lung neoplasms;
• development (in consultation with stakeholders) of new organisational solutions in therapeutic rehabilitation.